A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
NCT ID: NCT01634789
Last Updated: 2013-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
2 participants
INTERVENTIONAL
2012-08-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
NCT00367536
Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
NCT00479778
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women
NCT00464789
Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens
NCT00550303
Study Evaluating Bazedoxifene/CE in Postmenopausal Women
NCT00550433
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test Treatment 1: bazedoxifene
Test Treatment 1
bazedoxifene
20 mg oral tablet, single dose
Test Treatment 2: bazedoxifene
Test Treatment 2
bazedoxifene
20 mg oral tablet, single dose
Test Treatment 3: bazedoxifene
Test Treatment 3
bazedoxifene
20 mg oral tablet, single dose
Reference Treatment: bazedoxifene/conjugated estrogens
Reference Treatment
bazedoxifene/conjugated estrogens
20 mg / 0.625 mg oral tablet, single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bazedoxifene
20 mg oral tablet, single dose
bazedoxifene
20 mg oral tablet, single dose
bazedoxifene
20 mg oral tablet, single dose
bazedoxifene/conjugated estrogens
20 mg / 0.625 mg oral tablet, single dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) in the range of 18.0 to 35.0 kg/m2 and body weight \>= 50 kg
Exclusion Criteria
45 Years
64 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3115B1-1146
Identifier Type: -
Identifier Source: secondary_id
B2311014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.